1. What It Is (Mechanism of Action)

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA genome. It functions as an endocrine-like mitochondrial signaling peptide that translocates to the nucleus under metabolic stress to activate AMPK and regulate folate-purine biosynthesis.

2. Clinical Indications Under Study

Preclinical models of metabolic syndrome, insulin resistance, exercise capacity enhancement, and cellular senescence.

3. FDA Approval & Regulatory Status

Status:Unapproved Investigational Peptide (FDA 503A Category 2 List)

Unapproved Investigational Peptide (FDA 503A Category 2 List)

4. Human Clinical Evidence Summary

Human data is currently limited to observational correlation studies (measuring circulating endogenous MOTS-c in relation to age and insulin sensitivity) and early Phase 1 pharmacokinetic safety assessments. Lacks Phase 2/3 clinical efficacy trials.

5. Known Risks, Side Effects & Boxed Warnings

Unknown long-term human toxicity, potential metabolic dysregulation if AMPK is over-activated, and risks associated with unregulated peptide administration. Banned by WADA under Category S2 (Metabolic Modulators).

7. Why Gray-Market "Research Chemical" Versions Are Risky

Highly hydrophobic sequence that aggregates and precipitates easily. Gray-market vials frequently contain degraded polymers that cause intense inflammatory reactions.
Peptides Agora Intelligence Wire
Weekly Research Brief

Get Breaking MOTS-c Clinical Trial Alerts

Receive verified FDA dockets, Phase 3 readouts, and independent HPLC lab audits directly from our medical journalism desk.

HPLC Purity Audits
Independent lab test readouts & endotoxin assays
FDA PCAC Advisory
503A / 503B compounding votes and legal dockets
Phase 2/3 Readouts
Incretin & repair peptide clinical trial data
Zero vendor sponsorship or commercial advertisingUnsubscribe anytime with one click

8. Questions to Ask a Licensed Clinician

If you are discussing this compound with your doctor or healthcare provider, consider bringing these evidence-based questions:

  • Q1: What is the biological role of endogenous mitochondrial-derived peptides versus synthetic administration?
  • Q2: What evidence-based lifestyle and pharmacological interventions exist for metabolic health?

9. Primary Peer-Reviewed Sources & Citations

  • [1] Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces diet-induced obesity. Cell Metab. 2015;21(3):443-454. PubMed / Source →
  • [2] FDA 503A Category 2 Compounding Review on Mitochondrial Peptides. PubMed / Source →